Preventing peritoneal fibrosis - Insights from the laboratory

Peritoneal Dialysis International

Volumn 23, Issue SUPPL. 2, 2003, Pages

  Yung, Susan ^a   Chan, Tak Mao ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Extracellular matrix; Fibrosis; TGF 1; Vasculopathy

Indexed keywords

ADENOVIRUS VECTOR; AMINO ACID; COMPLEMENTARY DNA; CORTICOSTEROID; CYCLIC AMP; DECORIN; DIPYRIDAMOLE; FIBRONECTIN; GLUCOSE; GLUCOSE POLYMER; HEPARIN; INTEGRIN; MATRIX PROTEIN; OSMOTIC AGENT; PENTOXIFYLLINE; PERITONEAL DIALYSIS FLUID; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; CELL ACTIVATION; CELL CULTURE; CONCENTRATION (PARAMETERS); DRUG MECHANISM; EVIDENCE BASED MEDICINE; FIBROSIS; GENE THERAPY; HUMAN; IN VITRO STUDY; MICROVASCULATURE; NONHUMAN; PATHOGENESIS; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; REVIEW; TISSUE DISTRIBUTION; TISSUE PRESERVATION; TISSUE STRUCTURE; VASCULAR DISEASE; VIRAL GENE DELIVERY SYSTEM;

EID: 0345874657     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080302302s08     Document Type: Review

References (34)

1. Honda K, Nitta K, Horita S, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996; 72:171-6.
2. Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19: 517-25.
3. Williams JD, Craig KJ, Topley N, von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
4. Henderson IS, Couper IA, Lumsden A. Potentially irritant glucose metabolites in unused CAPD fluids. In: Maher JF, Winchester JF, eds. Frontiers in Peritoneal Dialysis. New York: Field, Rich and Associates; 1986: 261-4.
5. Topley N, Williams JD. The role of the peritoneal membrane in the control of inflammation in the peritoneal cavity. Kidney Int 1994; 46:S71-8.
6. Dobbie JW. Morphology of the peritoneum in CAPD. Blood Purif 1989; 7:74-85.
7. Di Paolo N, Sacchi G, de Mia M, Gaggiotti E, Capotondo L, Rossi P, et al. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis. Nephron 1986, 44:204-11.
8. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12:1046-51.
9. Lai KN, Lai KB, Lam CW, Chan TM, Li FK, Leung JC. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000; 35:644-52.
10. de Vriese AS, Tilton RG, Stephan CC, Lameire NH. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 2001; 12:1734-41.
11. Ogata S, Yorioka N, Kohno N. Glucose and prednisolone alter basic fibroblast growth factor expression in peritoneal mesothelial cells and fibroblasts. J Am Soc Nephrol 2001; 12:2787-96.
12. Border WA, Noble NA. TGFβ in kidney fibrosis. Kidney Int 1997; 51:1388-96.
13. Ha H, Yu MR, Lee HB. High glucose-induced PKC activation mediates TGFβ1 and fibronectin synthesis by peritoneal mesothelial cells. Kidney Int 2001; 59: 463-70.
14. Medcalf JF, Walls J, Pawlaczyk IZA, Harris KPG. Effects of glucose dialysate on extracellular matrix production by human peritoneal mesothelial cells (HPMC): the role of TGFβ. Nephrol Dial Transplant 2001; 16: 1885-92.
15. Fang CC, Yen CJ, Chen YM, Shyu RS, Tsai TJ, Lee PH, et al. Pentoxifylline inhibit human peritoneal mesothelial cell growth and collagen synthesis: effects on TGFβ. Kidney Int 2000; 57:2626-33.
16. Hung KY, Chen CT, Huang JW, Lee PH, Tsai TJ, Hsieh BS. Dipyridamole inhibits TGFβ-induced collagen gene expression in human peritoneal mesothelial cells. Kidney Int 2001; 60:1249-57.
17. Yung S, Liu ZH, Lai KN, Li LS, Chan TM. Emodin ameliorates glucose-induced morphologic abnormalities and synthesis of transforming growth factor β1 and fibronectin by human peritoneal mesothelial cells. Perit Dial Int 2001; 21:S41-7.
18. Wieslander A, Linden T, Musi B, Järkelid L, Speidel R, Beck W, et al. Exogenous uptake of carbonyl stress compounds promoting AGE formation from peritoneal dialysis fluids. Contrib Nephrol 2001; 131:82-9.
19. Holmes CJ, Shockley TR. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int 2000; 20:S37-41.
20. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12:2434-41.
21. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
22. Jones M, Hagen T, Boyle CA, Vonesh E, Hamburger R, Charytan C, et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study. Am J Kidney Dis 1998; 32:761-9.
23. Ha H, Cha MK, Choi HN, Lee HB. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002; 22:171-7.
24. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97:8015-20.
25. Chan TM, Leung JK, Tsang RC, Liu ZH, Li LS, Yung S. Emodin ameliorates glucose-induced matrix synthesis in human peritoneal mesothelial cells. Kidney Int 2003; 64:519-33.
26. Bottinger E, Factor V, Tsang M, Weatherbee J, Kopp J, Qian SW, et al. The recombinant proregion of transforming growth factor β1 (latency-associated peptide) inhibits active transforming growth factor β1 in transgenic mice. Proc Natl Acad Sci USA 1996; 93: 5877-82.
27. Sharma K, McGowan TA. TGF-β in diabetic kidney disease: role of novel signaling pathways. Cytokine Growth Factor Rev 2000; 11:115-23.
28. Yung S, Thomas GJ, Stylianou E, Williams JD, Coles GA, Davies M. Source of peritoneal proteoglycans. Human peritoneal mesothelial cells synthesize and secrete mainly small dermatan sulfate proteoglycans. Am J Pathol 1995; 146:520-9.
29. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002; 13:721-8.
30. Fracasso A, Baggio B, Ossi E, Del Prete D, Bonfante L, Bazzato G, et al. Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Am J Kidney Dis 1999; 33:105-10.
31. Gambaro G, Baggio B. Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol Dial Transplant 1996; 11:762-4.
32. Gastpar H, Ambrus JL, Ambrus CM, Spavento P, Wever FJ, Thurber LE. Study of platelet aggregation in vivo [I]. Effect of pentoxifylline. J Med 1997; 8:191-7.
33. Berman B, Duncan MR. Pentoxifylline inhibits normal human dermal fibroblast in vitro proliferation, collagen, glycosaminoglycan, and fibronectin production, and increases collagenase activity. J Invest Dermatol 1989; 82:605-10.
34. Yung S, Lui ZH, Li LS, Lai KN, Chan TM. Emodin ameliorates excessive fibronectin synthesis by human peritoneal mesothelial cells (HPMC) (Abstract). J Am Soc Nephrol 2001; 12:722A.